ArticleHepatology international2023
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Pooled it
- Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study.Scientific reports · 2026Article
- Precision Medicine in Inflammatory Bowel Disease: The Emerging Role of Metabolic Dysfunction.Journal of personalized medicine · 2026Review
- The Causal Association between Total Bilirubin, Direct Bilirubin, and Ulcerative Colitis: A Two-Sample Mendelian Randomization Study.Cell biochemistry and biophysics · 2025Article
- Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn's disease patients.BMC gastroenterology · 2025Article
- Association between questionnaire- and accelerometer-measured physical activity and incidence of cardiovascular disease in subjects with metabolic dysfunction-associated steatotic liver disease.American journal of preventive cardiology · 2025Article
- Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut-Liver Axis.Life (Basel, Switzerland) · 2025Article
- Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models.Frontiers in medicine · 2025Article
- Article
- Effect of dietary supplementation withFrontiers in veterinary science · 2025Article
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Multiomics analysis reveals the potential mechanism of high-fat diet in dextran sulfate sodium-induced colitis mice model.Food science & nutrition · 2024Article
- Dietary patterns in the progression of metabolic dysfunction-associated fatty liver disease to advanced liver disease: a prospective cohort study.The American journal of clinical nutrition · 2024Article
- Review
- Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative colitis.Scientific reports · 2024Article
- Sleep and liver function biomarkers in relation to risk of incident liver cancer: a nationwide prospective cohort study.BMC medicine · 2024Article
- Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease.Frontiers in immunology · 2024Article
- Landscape of surgery in Crohn's disease across twenty years: insights from machine learning.Translational gastroenterology and hepatology · 2024Article
- Associations between sex hormones, receptors, binding proteins and inflammatory bowel disease: a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Rapid quantification of 50 fatty acids in small amounts of biological samples for population molecular phenotyping.Biophysics reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is recently recognized as a condition featured with metabolic dysfunctions in liver. It has been supposed that MAFLD might contribute to the development of IBD, but evidence from prospective cohort studies is lacking and inconclusive.
methodsA total of 221,546 females and 183,867 males from the UK Biobank cohort enrolled in 2006-2010 were included to examine whether MAFLD and liver function markers were related to incident IBD. MAFLD was identified based on hepatic steatosis defined by fatty liver index plus the prevalence of overweight, type 2 diabetes mellitus, or at least two metabolic abnormalities. Biomarker related to liver function (albumin [ALB], alkaline phosphatase [ALP], alanine transaminase [ALT], aspartate transaminase [AST]; gamma-glutamyl transferase [GGT], total bilirubin [TB], total protein [TP]) was measured using colorimetric or enzymatic assays. The incidence of IBD was ascertained based on primary care and inpatient records. Cox proportional hazard model was used to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for the magnitude of their associations.
resultsWith a mean follow-up of 12.1 years, 2228 incident IBD cases were documented. We identified 150,385 individuals with MAFLD at baseline and 86% participants' circulating liver function markers were within the normal range. Participants with MAFLD were associated with a 12% (HR 1.12, 95% CI 1.03, 1.23, p = 0.012) increased risk of IBD compared with those without MAFLD at baseline; the association was stronger (p-
conclusionsIndividuals with MAFLD were at increased risk of developing IBD, especially CD, but not UC. Circulating levels of liver function biomarkers as the surrogate indicators of MAFLD were also associated with IBD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.